Neutralizing monoclonal antibodies have been shown to mediate central necrosis, and combination therapy with tumor-specific monoclonal antibodies may provide additional benefit. The interactions of VEGF biology with many other cytokines and cellular subcomponents of tumors are allowing a greater understanding of tumor biology and are giving insights into possible new antitumor strategies. Angiogenesis in cancer, vascular, rheumatoid and other disease. Vascular endothelial growth factor, a potent and selective angiogenic agent. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.